Cytokinetics (CYTK) vs Rhythm Pharmaceuticals (RYTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rhythm Pharmaceuticals (RYTM) has outperformed Cytokinetics (CYTK) over the past year, gaining 10.4% versus a loss of 22.4%. Over five years, RYTM leads with a +1116.0% price change compared with +30.1% for CYTK. Rhythm Pharmaceuticals is the larger company by market cap ($7.79 billion vs $7.07 billion), about 1.1 times the size, while Cytokinetics is growing revenue faster (+376.6% vs +45.8%).
Rhythm Pharmaceuticals converts more of its revenue into profit, with a net margin of -103.6% versus -891.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CYTK | RYTM |
|---|---|---|
| Share price | $50.78 | $112.36 |
| Market cap | $7.07B | $7.79B |
| 1-day change | -1.32% | -3.80% |
| YTD return | -20.08% | +4.97% |
| 1-year return | -22.40% | +10.44% |
| 5-year return | +30.11% | +1116.02% |
| EPS (TTM) | $-6.02 | $-2.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $88.04M | $189.76M |
| Revenue growth (YoY) | +376.56% | +45.83% |
| Net income (latest FY) | $-784.96M | $-196.54M |
| Gross margin | — | 89.73% |
| Operating margin | -695.44% | -101.19% |
| Net margin | -891.60% | -103.57% |
| 52-week high | $88.31 | $122.20 |
| 52-week low | $50.32 | $74.50 |
| Distance from 52-week high | -42.50% | -8.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +115.48% | +24.71% |
| Average volume | 2.02M | 1.10M |
| Shares outstanding | 139.30M | 69.33M |
| Employees | 673 | 414 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RYTM has outperformed CYTK by 32.8 percentage points over the past year.
- Rhythm Pharmaceuticals is more profitable, keeping -103.6 cents of every revenue dollar as net income versus -891.6 cents for Cytokinetics.
- Cytokinetics grew revenue faster in its latest fiscal year (+376.56% vs +45.83%).
About Cytokinetics
CYTK stock →Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Health Care · Biotechnology: Pharmaceutical Preparations · 673 employees
About Rhythm Pharmaceuticals
RYTM stock →Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees
CYTK vs RYTM FAQ
Which is bigger, Cytokinetics or Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals (RYTM) is larger, with a market capitalization of $7.79B compared with $7.07B for Cytokinetics (CYTK).
Which stock has performed better over the past year, CYTK or RYTM?
RYTM returned +10.44% over the past 12 months, compared with -22.40% for CYTK (price return, excluding dividends). Past performance does not predict future results.
Are Cytokinetics and Rhythm Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.